ACET Stock Analysis: Buy, Sell, or Hold?
ACET - Adicet Bio, Inc. Common Stock
$9.00
0.38 (4.41%)
▲
5d:
+13.92%
30d:
+10.97%
90d:
+30.81%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When ACET Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ACET shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ACET shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ACET is currently trading at $9.00, which is considered extended relative to its 30-day fair value range of $7.63 to $8.67.
Technical Outlook: Technically, ACET is in a uptrend. Immediate support is located at $7.86, while resistance sits at $9.39. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: ACET has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.83 (+287.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ACET is in a uptrend. Immediate support is located at $7.86, while resistance sits at $9.39. The stock is showing strong short-term momentum, up 4.4% recently.
Market Sentiment: ACET has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $34.83 (+287.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$7.63 -
$8.67
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.4%)
- BULLISH: Trading 287.0% below Wall St target ($34.83)
Trading Range Analysis
30-Day Trading Range
$7.63 -
$8.67
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$7.86
Resistance Level
$9.39
Current Trend
Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.15
Wall Street Target
$34.83
(+287.0%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: July 04, 2026 12:51 AM ET
Data refreshes hourly during market hours. Next update: 1:51 AM
Data refreshes hourly during market hours. Next update: 1:51 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACET showing a specific setup today?
Insider Activity (6 Months)
3
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Ra Capital Management, L…
BUY
74751 shares
2026-02-20
Ra Capital Management, L…
BUY
74268 shares
2026-02-19
Ra Capital Management, L…
BUY
74577 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 56 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$106 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 54 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$110 | 61 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 57 HOLD |
